MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors
February 21, 2019 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of...
MeiraGTx to Present at the BIO CEO & Investor Conference
February 05, 2019 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases
January 31, 2019 06:30 ET
|
MeiraGTx
-- Conference call and webcast today, January 31, 2019 at 8:30 a.m. EST -- MeiraGTx to receive $100 million cash upfront payment upon closing -- MeiraGTx to receive 20% net sales royalties and...
MeiraGTx to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson’s Disease
December 12, 2018 08:30 ET
|
MeiraGTx
Findings Published in Science Translational Medicine Show AAV-GAD Exerts Clinical Benefits by Inducing the Formation of New Brain Pathways Results Expand on Findings from Completed Phase 2 Clinical...
MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the...
MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia
October 31, 2018 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced an exclusive...
MeiraGTx Expands Leadership Team with Appointment of Katherine Breedis as Chief Financial Officer
October 25, 2018 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that on October 2nd, 2018,...
MeiraGTx Enters Collaboration with Johnson & Johnson Innovation to Develop Regulatable Gene Therapy Treatment using MeiraGTx Riboswitch Technology
October 16, 2018 08:00 ET
|
MeiraGTx
LONDON and NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a...
MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson’s Disease
October 09, 2018 07:00 ET
|
MeiraGTx
LONDON and NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has acquired Vector...